MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/hiv.70231

Медицинская библиотека · HIV medicine · 2026

Hepatitis B reactivation in people living with HIV and isolated anti-HBc receiving tenofovir-sparing dual antiretroviral therapy.

Arcos-Rueda M D M, De Miguel-Buckley R, De Gea Grela A, Busca C, Mican R, Montejano R, Falces-Romero I, Montes M L, Bernardino J I, González García J, Martin-Carbonero L

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Isolated hepatitis B core antibody (anti-HBc pos, anti-HBs neg, HBsAg neg) serology is frequently observed in people living with HIV. It typically indicates a resolved hepatitis B virus (HBV) infection but may also reflect occult HBV infection, with a potential risk of reactivation. Tenofovir (TFV) containing antiretroviral therapy (ART) effectively suppresses HBV replication; however, TFV-sparing dual regimens are increasingly used. This study evaluates evidence of HBV reactivation in people living with HIV with isolated anti-HBc patterns receiving TFV-sparing dual ART.

METHODS

We conducted a single-centre cross-sectional study. All people living with HIV receiving TFV-sparing dual ART with a documented prior isolated anti-HBc serological pattern who attended routine clinical visits between April 2024 and March 2025 were invited to participate. HBV serologies and HBV DNA were performed at the study visit. Reactivation was considered as the presence of HBV-DNA or HBsAg.

RESULTS

Among the 4006 people living with HIV in our cohort, 1499 (37.4%) had serological evidence of prior HBV exposure and 386 had a history of isolated anti-HBc serology. The isolated anti-HBc pattern was confirmed in 77 participants receiving TFV-sparing regimens: 57 on dolutegravir (DTG) plus lamivudine (3TC), 13 on DTG plus rilpivirine and 7 on long-acting cabotegravir plus rilpivirine. Median age was 60 years (interquartile range [IQR] 57-62), 83% were male, 84% had prior hepatitis C virus (HCV) coinfection, and the median time on the TFV-sparing regimen was 3.36 years (IQR 2.79-3.93). Among the 20 participants receiving regimens without any HBV-active drugs (no TFV or 3TC), no evidence of HBV reactivation was detected. One participant receiving DTG plus 3TC showed a transient, unconfirmed HBV DNA blip (29 IU/mL), not associated with transaminase increase.

CONCLUSIONS

In this cross-sectional assessment, no evidence of HBV reactivation was detected in people living with HIV with isolated anti-HBc receiving TFV-sparing dual ART, including regimens without direct anti-HBV activity.

Для цитирования: Arcos-Rueda M D M, De Miguel-Buckley R, De Gea Grela A, Busca C, Mican R, Montejano R, Falces-Romero I, Montes M L, Bernardino J I, González García J, Martin-Carbonero L. Hepatitis B reactivation in people living with HIV and isolated anti-HBc receiving tenofovir-sparing dual antiretroviral therapy.. HIV medicine. 2026. DOI: 10.1111/hiv.70231.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.